Roche Exits RNAi, Raising Questions For Stalwarts
In mid-November, in a move that seemingly came from the top, Roche opted to cease all activity in RNA interference technology, preferring to invest in other areas like next-generation antibodies and peptide therapeutics. These days RNAi company Alnylam might have some difficult questions to answer about its business development strategy - only nobody's really asking. That's because even as Roche weighs its options around divestiture of its RNAi license, technology and research sites, the future of Alnylam - and the field of RNAi more generally - is now tied solely to establishing clinical proof-of-concept for siRNA drugs, and eventually getting those drugs to market.
You may also be interested in...
Juno Therapeutics and Moderna Therapeutics both leveraged promising technologies to bring home venture rounds of more than $100 million in recent weeks. Plus news on recent financings by Argos Therapeutics, Xencor, Sitari and 5am Ventures.
While interest in microRNA may not be moving at the speed that some investors (and, certainly, some smaller companies) may like, Big Pharma has taken notice of the little oligos and is watching the sector.
Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.